Cerus (NASDAQ:CERS) Insider Sells $61,998.45 in Stock

Cerus Corporation (NASDAQ:CERS) insider Chrystal Jensen sold 30,845 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.01, for a total value of $61,998.45. Following the sale, the insider directly owned 1,059,139 shares of the company’s stock, valued at $2,128,869.39. This represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Cerus Stock Up 1.1%

Shares of CERS opened at $1.79 on Thursday. The firm has a market capitalization of $343.98 million, a P/E ratio of -22.38 and a beta of 1.51. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. Cerus Corporation has a 12-month low of $1.12 and a 12-month high of $2.96. The firm has a fifty day moving average price of $2.30 and a 200-day moving average price of $1.86.

Cerus (NASDAQ:CERS) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). The business had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. Equities research analysts expect that Cerus Corporation will post -0.08 earnings per share for the current year.

Institutional Trading of Cerus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new stake in Cerus during the 4th quarter valued at about $25,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Cerus during the third quarter worth about $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cerus during the first quarter worth about $32,000. Aquatic Capital Management LLC purchased a new stake in Cerus in the third quarter valued at approximately $35,000. Finally, MML Investors Services LLC acquired a new position in Cerus in the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. TD Cowen reiterated a “buy” rating on shares of Cerus in a research note on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.